News & Events
PRESS RELEASE | Jul. 20, 2026
TheraVac Biologics Featured in Inside Precision Medicine for Novel Alzheimer's Vaccine Platform
TheraVac’s Scientific Co-Founder, Dr. Kiran Bhaskar, featured in Inside Precision Medicine’s article, “Stopping Neurodegeneration in Place with Vaccines”
PRESS RELEASE | Nov. 28, 2025
TheraVac Biologics Awarded Funding Through CABHI Fuel Program to Advance Immunotherapies for Neurodegenerative Diseases
TheraVac is one of eight innovators awarded funding in the latest cohort of CABHI Fuel.
PRESS RELEASE | Sept. 10, 2025
TheraVac Biologics Signs License Agreement with University of New Mexico Health Sciences Center to Advance VLP-Based Immunotherapies for Neurodegenerative and Chronic Inflammatory Disease
Agreement supports clinical development and commercialization of novel therapies targeting tau pathology and the inflammasome complex.
PRESS RELEASE | June 13, 2025
TheraVac Biologics Announces $1 Million Grant Award from Part the Cloud to Advance Novel Tau Vaccine for Alzheimer’s Disease
Funding to support development of a virus-like particle–based immunotherapy targeting tauopathies.
PRESS RELEASE | Jan. 13, 2025
TheraVac Biologics Partners with Perceiv AI to Optimize Clinical Trials Using Advanced AI and Prognostic Biomarkers
Jan. 13, 2025 – San Francisco – TheraVac Biologics, a company developing innovative immunotherapies for neurological and autoimmune disease is thrilled to announce a strategic partnership with Perceiv AI.
VIRTUAL KOL Event | Nov. 12, 2024
Alzheimer’s Immunotherapies Targeting Tau Protein; Update on TV-301, A Phospho-Tau vaccine
PRESS RELEASE | Sept. 16, 2024
TheraVac Biologics Announces Allowance of U.S. Patent Covering Inflammasome-Targeting Immunotherapy Compositions
Sept. 16, 2024, ALBUQUERQUE, NM & MISSISSAUGA, ON – TheraVac Biologics announces U.S. patent covering novel vaccine candidates for the treatment of multiple chronic conditions caused by inflammasome overactivation.
PRESS RELEASE | Nov. 10, 2023
TheraVac Biologics Announces Exclusive Option Agreement with the University of New Mexico for Groundbreaking Vaccine Technology
Nov. 10, 2023, Albuquerque, NM & Mississauga, ON – TheraVac Biologics is pleased to announce that it has entered into an exclusive option agreement with the University of New Mexico.